EGFR-Mutated Lung Cancer With T790M-Acquired Resistance in the Brain and Histologic Transformation in the Lung

被引：31
|
作者：
Scher, Kevin S. [1 ]
Saldivar, Juan-Sebastian [1 ]
Fishbein, Michael [2 ]
Marchevsky, Alberto [3 ]
Reckamp, Karen L. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Cedars Sinai Med Ctr, Hollywood, CA USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 09期
关键词：
ERLOTINIB; GEFITINIB;
D O I：
10.6004/jnccn.2013.0126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.
引用
收藏
页码：1040 / 1044
页数：5
相关论文
共 50 条
  • [1] Acquired T790M resistance do afatinib in EGFR mutated lung adenocarcinoma
    Miyazaki, Kunihiko
    Sato, Shinya
    Kodama, Takahide
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2016, 64 (04): : 317 - 318
  • [2] A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib Evaluating for a T790M Mutation With Limited Tissue
    Wynja, Emily
    Hove, Jenna
    Powell, Steven F.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 499 - 500
  • [3] Managing Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Forde, Patrick M.
    Ettinger, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 528 - 532
  • [4] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [5] 3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance
    Brosseau, Solenn
    Viala, Marie
    Varga, Andrea
    Planchard, David
    Besse, Benjamin
    Soria, Jean-Charles
    BULLETIN DU CANCER, 2015, 102 (09) : 749 - 757
  • [6] OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report
    Reactions Weekly, 2021, 1836 (1) : 619 - 619
  • [7] Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer
    Haratake, Naoki
    Misumi, Toshihiro
    Yamanaka, Takeharu
    Seto, Takashi
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [8] Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
    Vojnic, Morana
    Kubota, Daisuke
    Kurzatkowski, Christopher
    Offin, Michael
    Suzawa, Ken
    Benayed, Ryma
    Schoenfeld, Adam J.
    Plodkowski, Andrew J.
    Poirier, John T.
    Rudin, Charles M.
    Kris, Mark G.
    Rosen, Neal X.
    Yu, Helena A.
    Riely, Gregory J.
    Arcila, Maria E.
    Somwar, Romel
    Ladanyi, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 802 - 815
  • [9] Association of Initial PD-L1 Expression with T790M-Acquired Resistance in Advanced EGFR-Mutant Lung Adenocarcinoma Patients
    Nishino, K.
    Kubota, A.
    Kunimasa, K.
    Kimura, M.
    Inoue, T.
    Tamiya, M.
    Kuhara, H.
    Kumagai, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S380 - S380
  • [10] Combination Therapy for EGFR-Mutated Lung Cancer
    Wu, Yi-Long
    Zhou, Qing
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 2005 - 2007
12345